.png)
Pioneering the development of first-in-class small molecules that target transcription-replication conflict in HRD (BRCA) solid tumors, this groundbreaking approach leverages novel compounds derived from tropical plants. These innovative molecules offer new hope for cancer patients and carriers.
.png)
.png)
Our unique, natural product-inspired drug discovery process has been incredibly successful in identifying a promising lead molecule, (NB1001) derived from a tropical medicinal plant from Singapore and Malaysia. NB1001 have been engineered with its derivative (NB1002) to exhibit enhanced potent anti-cancer activity, effectively instigating synthetic lethality through Transcription-Replication Conflicts in Homologous Recombination Deficiency (HRD) cancers (E.g Triple Negative BRCA (-/-) Breast Cancer).
Preclinical studies highlight the potential of NB1001 and NB1002 across various HRD cancers. This breakthrough offers a transformative approach to cancer treatment, providing a prophylactic barrier for high-risk groups, including BRCA mutation carriers, by preemptively targeting potential malignant transformations.
.png)
